170 related articles for article (PubMed ID: 15939134)
1. [Dihydropyrimidine deshydrogenase (DPD): rhythm and consequences].
Barrat-Petit MA; Naulin-Ifi C; Mahler P; Milano G
Pathol Biol (Paris); 2005 Jun; 53(5):261-4. PubMed ID: 15939134
[TBL] [Abstract][Full Text] [Related]
2. Circadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls.
Raida M; Kliche KO; Schwabe W; Häusler P; Clement JH; Behnke D; Höffken K
J Cancer Res Clin Oncol; 2002 Feb; 128(2):96-102. PubMed ID: 11862480
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
6. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats.
Taniguchi M; Yano M; Tsujinaka T; Ogawa A; Morita S; Kaneko K; Akiyama Y; Miki H; Monden M
In Vivo; 2003; 17(3):219-23. PubMed ID: 12929570
[TBL] [Abstract][Full Text] [Related]
7. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
Milano G; Etienne MC
Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
10. [Circadian variations of dihydropyrimidine dehydrogenase (DPD) activity in oral mucosa of healthy volunteers].
Barrat MA; Renée N; Mormont MC; Milano G; Levi F
Pathol Biol (Paris); 2003 Jun; 51(4):191-3. PubMed ID: 12852985
[TBL] [Abstract][Full Text] [Related]
11. Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
Furuhata T; Kawakami M; Okita K; Kimura Y; Kihara C; Tsuruma T; Ohmura T; Yamaguchi K; Hata F; Katsuramaki T; Sasaki K; Hirata K
J Exp Clin Cancer Res; 2006 Mar; 25(1):79-82. PubMed ID: 16761622
[TBL] [Abstract][Full Text] [Related]
12. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Lee A; Ezzeldin H; Fourie J; Diasio R
Clin Adv Hematol Oncol; 2004 Aug; 2(8):527-32. PubMed ID: 16163233
[TBL] [Abstract][Full Text] [Related]
14. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
[TBL] [Abstract][Full Text] [Related]
15. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
[TBL] [Abstract][Full Text] [Related]
16. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
Serdar MA; Sertoğlu E; Uyanık M; Tapan S; Akın O; Cihan M
Cancer Chemother Pharmacol; 2011 Aug; 68(2):525-9. PubMed ID: 21107571
[TBL] [Abstract][Full Text] [Related]
17. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
[TBL] [Abstract][Full Text] [Related]
18. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
Jiang H; Lu J; Ji J
Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
[TBL] [Abstract][Full Text] [Related]
19. [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
Etienne MC; Milano G; Fleming RA; Thyss A; Renée N; Schneider M; Demard F
Bull Cancer; 1992; 79(12):1159-63. PubMed ID: 1304835
[TBL] [Abstract][Full Text] [Related]
20. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients.
Zeng ZL; Sun J; Guo L; Li S; Wu MW; Qiu F; Jiang WQ; Lévi F; Xian LJ
Chronobiol Int; 2005; 22(4):741-54. PubMed ID: 16147904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
